The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2022.

Roche Diagnostics plans to bring a fully automated mass spectrometry-based clinical analyzer to market in 2024.

After three years, China announced its reopening from January 8, 2023. Passengers can enter China without quarantine. All you need is a negative PCR result within 48 hours before departure. You do not need to apply for a health code.

After three years, China announced its reopening from January 8, 2023. Passengers can enter China without quarantine. All you need is a negative PCR result within 48 hours before departure. You do not need to apply for a health code.

Beckman Coulter Diagnostics announced on Tuesday that it has entered a strategic partnership with Israeli diagnostic company MeMed to develop and commercialize a host immune response diagnostic test.

Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2022.

On January 31, A-share listed Daan Gene released the 2022 full-year performance forecast.

Precision oncology company Guardant Health announced on Monday that FDA has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic.

SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2022.

Easy Diagnosis released a performance preview on the evening of January 30, expecting 2022 net profit attributable to shareholders of listed companies of CNY4.6 billion to CNY5 billion, an increase of 225.5% to 253.8%; basic earnings per share of about CNY29.99 to CNY32.60.